

Global Journal of Clinical Medicine and Medical Research [GJCMMR]
ISSN: 2583-987X (Online)
Abbreviated key title: Glob.J.Clinic.Medici.Medica.Res.
Frequency: Monthly
Published By GSAR Publishers
Journal Homepage Link- https://gsarpublishers.com/journal-gjcmmr-home/

Hepatocellular Carcinoma: Exploring the Efficacy of Targeted and Combination Therapies

BY

Kirolos Eskandar

Diakonie Klinik Mosbach – Germany ORCID ID: https://orcid.org/0000-0003-0085-3284

Article History

Received: 01/07/2024
Accepted: 08/07/2024
Published: 09/07/2024

Vol – 2 Issue – 7

PP: -01-06

Abstract

Hepatocellular carcinoma (HCC) represents a significant global health burden, characterized by high morbidity and mortality rates. Despite advances in early detection and standard treatments, the prognosis for advanced HCC remains poor, necessitating innovative therapeutic strategies. This literature review delves into the epidemiology and pathogenesis of HCC, elucidating the underlying mechanisms that drive its progressi on. We comprehensively explore current standard therapies, highlighting their limitations and the pressing need for novel interventions. The advent of targeted therapies, particularly tyrosine kinase inhibitors, has revolutionized HCC treatment, offering new hope despite emerging resistance issues. Immunotherapy, especially immune checkpoint inhibitors, has also shown promising potential, either as monotherapy or in combination with other treatments. Furthermore, the synergistic effects of combination therapies are examined, underscoring their potential to enhance therapeutic efficacy and overcome resistance. This review aims to provide a detailed analysis of the efficacy of targeted and combination therapies in HCC, paving the way for future research and clinical advancements.

Keywords: *Hepatocellular Carcinoma, Targeted Therapy, Immunotherapy, Combination Therapy, Tyrosine Kinase Inhibitors.*

I. INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, accounting for approximately 75-85% of all liver cancer cases globally. It ranks as the sixth most frequently diagnosed cancer and the fourth leading cause of cancer-related mortality worldwide, reflecting its significant impact on public health [1]. The burden of HCC is particularly pronounced in regions with high prevalence of hepatitis B and C virus infections, such as East Asia and sub-Saharan Africa, where chronic viral hepatitis is a major etiological factor [2]. Additional risk factors include chronic alcohol consumption, non-alcoholic fatty liver disease (NAFLD), obesity, diabetes, and exposure to aflatoxins [3].

The pathogenesis of HCC is a complex, multistep process involving genetic, epigenetic, and environmental factors. Chronic liver inflammation and cirrhosis, regardless of etiology, are critical drivers of hepatocarcinogenesis. The intricate interplay between hepatocyte damage, regenerative proliferation, and the liver's microenvironment fosters a milieu conducive to malignant transformation [4]. Molecular alterations, including mutations in key oncogenes and tumor suppressor genes, aberrant signaling pathways (such as Wnt/β-catenin, PI3K/Akt/mTOR, and MAPK), and epigenetic modifications, further facilitate HCC development and progression [5].

Despite advancements in diagnostic modalities that enable earlier detection, the prognosis for HCC patients remains dismal, especially for those with advanced disease. Traditional treatment modalities, including surgical resection, liver transplantation, and locoregional therapies (such as radiofrequency ablation and transarterial chemoembolization), are often limited by tumor stage, liver function, and patient performance status [6]. These limitations underscore the urgent need for more effective systemic therapies.

In recent years, the introduction of targeted therapies has marked a significant milestone in the management of HCC. Tyrosine kinase inhibitors (TKIs), such as sorafenib and lenvatinib, have been approved for first-line treatment of advanced HCC, demonstrating a modest improvement in overall survival [7]. However, the emergence of drug resistance and adverse effects remains a considerable challenge, prompting ongoing research into novel agents and combination strategies [8].

Immunotherapy, particularly immune checkpoint inhibitors like nivolumab and pembrolizumab, has emerged as a promising therapeutic approach, leveraging the host immune

*Corresponding Author: **Kirolos Eskandar**

© Copyright 2024 GSAR Publishers All Rights Reserved

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

system to combat cancer cells. Early clinical trials have shown encouraging results, although the efficacy of immunotherapy as a monotherapy varies among patients [9]. Consequently, combining immunotherapy with other treatment modalities, such as TKIs and locoregional therapies, is being extensively investigated to enhance therapeutic outcomes [10].

This literature review aims to provide a comprehensive analysis of the current and emerging therapeutic strategies for HCC, with a particular focus on the efficacy of targeted and combination therapies. By exploring the latest clinical trial data, mechanisms of action, and potential future directions, we seek to elucidate the evolving landscape of HCC treatment and highlight opportunities for improving patient prognosis and quality of life.

II. Epidemiology and Pathogenesis of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) represents a significant global health burden, characterized by its high incidence and mortality rates. According to GLOBOCAN 2018 data, HCC ranks as the sixth most common cancer worldwide, with over 840,000 new cases annually and approximately 782,000 deaths [11]. Geographical disparities in HCC incidence reflect varying distributions of major risk factors such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. Regions with high HBV prevalence, notably East Asia and sub-Saharan Africa, exhibit elevated HCC rates, with China alone contributing more than half of the global cases due to chronic HBV infections [12]. Conversely, in regions like Japan, Southern Europe, and the United States, HCV plays a predominant role in HCC etiology, alongside rising rates of non-alcoholic fatty liver disease (NAFLD) [13].

The pathogenesis of HCC is multifaceted, involving several established risk factors. Chronic HBV and HCV infections are primary drivers of hepatocarcinogenesis, inducing chronic inflammation, fibrosis, and ultimately cirrhosis, which predisposes to HCC development [14]. Alcohol consumption is another significant risk factor, synergistically increasing HCC risk in individuals with viral hepatitis. Chronic alcohol abuse contributes to liver cirrhosis, a major precursor to HCC [15]. NAFLD, encompassing a spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH), has emerged as a growing risk factor for HCC, capable of promoting liver carcinogenesis independently of cirrhosis [16]. Genetic predispositions, including mutations in genes like TP53 and CTNNB1, and hereditary conditions such as hemochromatosis, further augment HCC susceptibility [17].

At the molecular level, HCC pathogenesis involves intricate genetic and epigenetic alterations. Mutations in oncogenes and tumor suppressor genes disrupt critical signaling pathways, including the Wnt/β-catenin and PI3K/Akt/mTOR pathways, promoting uncontrolled cell proliferation and survival [18]. Dysregulation of MAPK signaling and epigenetic modifications such as DNA methylation and altered microRNA expression contribute to the molecular heterogeneity of HCC, influencing its progression and therapeutic response [19, 20].

III. Current Standard Therapies for Hepatocellular Carcinoma

The management of hepatocellular carcinoma (HCC) involves a multifaceted approach tailored to the tumor stage, liver function, and patient performance status. Surgical resection is considered the cornerstone treatment for early-stage HCC, offering the potential for cure. It involves the removal of the tumor along with a margin of healthy liver tissue. Surgical resection is most effective in patients with single, small tumors and well-preserved liver function, typically classified as Child-Pugh A cirrhosis. However, many patients are diagnosed at a more advanced stage or have underlying liver disease that precludes surgical intervention [21].

Liver transplantation is another curative option, particularly suitable for patients with early-stage HCC and underlying cirrhosis. It offers the dual benefit of removing the tumor and treating the cirrhotic liver. Selection criteria for transplantation, such as the Milan criteria, are stringent, requiring tumors to be within specific size and number limits to optimize outcomes. Despite its curative potential, liver transplantation faces challenges including organ shortage, the risk of tumor recurrence, and the need for lifelong immunosuppression [22].

For patients who are not candidates for surgery, locoregional therapies provide alternative treatment options. Radiofrequency ablation (RFA) is a minimally invasive procedure that uses thermal energy to destroy cancer cells. It is most effective for small tumors (typically less than 3 cm in diameter) and is often employed in patients with early-stage HCC who are not surgical candidates. Transarterial chemoembolization (TACE) is another widely used locoregional therapy, particularly for intermediate-stage HCC. TACE involves the administration of chemotherapeutic agents directly into the hepatic artery supplying the tumor, followed by embolization to obstruct the blood flow, thus enhancing the cytotoxic effect. TACE has been shown to improve survival in patients with unresectable HCC, though it is not curative and is associated with complications such as post-embolization syndrome and liver dysfunction [23].

Despite the availability of these conventional therapies, they are associated with several limitations and challenges. Surgical resection and liver transplantation are only feasible for a subset of patients due to the advanced stage at diagnosis or poor liver function in many cases. Furthermore, even after successful resection or transplantation, there is a substantial risk of tumor recurrence, necessitating close follow-up and potentially additional treatments. Locoregional therapies, while less invasive, are typically palliative rather than curative and often require repeated sessions to control tumor growth. Moreover, these procedures can be technically challenging and are associated with complications such as bleeding, infection, and liver failure, particularly in patients with compromised liver function [24].

*Corresponding Author: **Kirolos Eskandar**
© Copyright 2024 GSAR Publishers All Rights Reserved

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The limitations of these traditional approaches highlight the need for more effective systemic therapies and novel treatment strategies. Advancements in understanding the molecular and genetic underpinnings of HCC have paved the way for targeted therapies and immunotherapies, which aim to improve outcomes for patients with advanced disease. Nonetheless, the optimal integration of these newer modalities with existing treatment paradigms remains an area of active research and clinical investigation [25].

IV. Targeted Therapies in Hepatocellular Carcinoma

The advent of targeted therapies has significantly transformed the landscape of hepatocellular carcinoma (HCC) treatment, particularly for patients with advanced disease who are not candidates for curative interventions. Tyrosine kinase inhibitors (TKIs) have emerged as a cornerstone of targeted therapy in HCC, with sorafenib being the first agent to demonstrate a survival benefit in this patient population. Sorafenib, a multi-kinase inhibitor, targets the Raf/MEK/ERK pathway as well as receptor tyrosine kinases such as VEGFR and PDGFR. Its efficacy was established in the pivotal SHARP trial, which showed that sorafenib significantly improved overall survival compared to placebo (10.7 months vs. 7.9 months) in patients with advanced HCC [26]. The subsequent Asia-Pacific trial further confirmed these findings in a predominantly Asian population [27].

Following the success of sorafenib, lenvatinib, another multi-kinase inhibitor, was introduced as an alternative first-line treatment. Lenvatinib targets VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT, offering a broader spectrum of activity compared to sorafenib. The REFLECT trial demonstrated that lenvatinib was non-inferior to sorafenib in terms of overall survival (13.6 months vs. 12.3 months) and showed significant improvements in secondary endpoints such as progression-free survival and objective response rate [28]. These findings have established lenvatinib as a viable first-line option, expanding the therapeutic arsenal for HCC.

Despite the efficacy of TKIs, resistance to these agents poses a significant challenge. Primary and acquired resistance mechanisms often limit the long-term success of TKI therapy. Primary resistance may arise from intrinsic factors within the tumor microenvironment or genetic heterogeneity, while acquired resistance typically develops through adaptive changes during treatment. Common resistance mechanisms include upregulation of alternative signaling pathways, mutations in the target kinases, and activation of compensatory angiogenic factors [29]. For instance, activation of the PI3K/Akt/mTOR pathway has been implicated in resistance to both sorafenib and lenvatinib, highlighting the need for combination strategies that target multiple pathways simultaneously [30].

Strategies to overcome resistance are an active area of research. Combination therapies involving TKIs and other agents, such as immune checkpoint inhibitors or additional targeted therapies, are being explored. For example, the combination of lenvatinib and pembrolizumab, an anti-PD-1 antibody, has shown promising preliminary results, with improved response rates and survival outcomes compared to monotherapy in early-phase trials [31]. Additionally, ongoing studies are investigating the role of biomarkers to predict response to TKIs and guide personalized treatment approaches, aiming to optimize efficacy and minimize resistance.

V. Immunotherapy and Its Role in Hepatocellular Carcinoma Treatment

Immunotherapy has emerged as a groundbreaking approach in the treatment of hepatocellular carcinoma (HCC), particularly for patients with advanced disease who have limited options following the failure of traditional therapies. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have been at the forefront of this therapeutic revolution. These agents target regulatory pathways in T cells to enhance the immune system's ability to recognize and destroy cancer cells. Nivolumab, an anti-PD-1 antibody, was the first immunotherapy approved for HCC based on the results of the CheckMate 040 trial, which demonstrated a manageable safety profile and durable responses in a subset of patients [32]. Pembrolizumab, another PD-1 inhibitor, was subsequently evaluated in the KEYNOTE-224 study, showing promising antitumor activity and an acceptable safety profile [33].

The success of immune checkpoint inhibitors as monotherapy has paved the way for exploring combination strategies aimed at enhancing their efficacy. Combining immunotherapy with targeted therapies or chemotherapy represents a promising strategy to overcome resistance mechanisms and achieve synergistic antitumor effects. For instance, the combination of atezolizumab, an anti-PD-L1 antibody, with bevacizumab, an anti-VEGF antibody, has shown significant improvement in overall survival and progression-free survival compared to sorafenib in the IMbrave150 trial [34]. This combination leverages the complementary mechanisms of immune activation and angiogenesis inhibition, providing a potent therapeutic approach for HCC.

In addition to targeted therapy, combining immunotherapy with locoregional treatments, such as radiofrequency ablation or transarterial chemoembolization, is being actively investigated. These locoregional therapies can modulate the tumor microenvironment and potentially enhance the immune response by increasing tumor antigen release and reducing immunosuppressive factors [35]. Early-phase studies suggest that such combinations may improve clinical outcomes, but further research is needed to validate these findings and optimize treatment protocols.

Despite the promising results, challenges remain in the implementation of immunotherapy for HCC. Not all patients respond to immune checkpoint inhibitors, and the identification of predictive biomarkers is crucial for selecting patients who are most likely to benefit from these treatments. Moreover, immune-related adverse events, although generally

*Corresponding Author: **Kirolos Eskandar**
© Copyright 2024 GSAR Publishers All Rights Reserved

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

manageable, can be severe and require careful monitoring and management [36].

Ongoing research continues to explore the full potential of immunotherapy in HCC. Numerous clinical trials are underway to evaluate novel immunotherapeutic agents, combinations with other therapies, and optimal sequencing of treatments. Additionally, research into the tumor immune microenvironment and mechanisms of immune evasion will provide insights into overcoming resistance and enhancing the efficacy of immunotherapy [37].

VI. Combination Therapies: Synergistic Approaches in Treating Hepatocellular Carcinoma

The rationale for combination therapies in hepatocellular carcinoma (HCC) stems from the multifaceted nature of the disease and the limitations of monotherapy in achieving long-term control. Combining different therapeutic modalities aims to enhance efficacy by targeting multiple pathways simultaneously, overcoming resistance mechanisms, and potentially improving survival outcomes. Combination therapies can exploit the synergistic effects of various agents, including targeted therapies, immunotherapies, and traditional approaches such as chemotherapy and locoregional treatments, to provide a more comprehensive attack on the tumor and its microenvironment.

One of the most notable examples of a successful combination regimen is the use of atezolizumab (an anti-PD-L1 antibody) with bevacizumab (an anti-VEGF antibody). The IMbrave150 trial demonstrated that this combination significantly improved overall survival and progression-free survival compared to sorafenib, a standard monotherapy, in patients with unresectable HCC. The synergistic effect of immune checkpoint inhibition and anti-angiogenesis leads to a more effective antitumor response by enhancing T-cell infiltration and reducing immunosuppressive factors within the tumor microenvironment [38]. This landmark study has established the atezolizumab-bevacizumab combination as a new standard of care for first-line treatment of advanced HCC.

Beyond this, other combinations involving tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors are under investigation. For instance, the combination of lenvatinib and pembrolizumab has shown promising antitumor activity and manageable safety profiles in early-phase trials. This combination targets both angiogenic pathways and immune checkpoints, thereby attacking the tumor through multiple mechanisms and enhancing the immune-mediated killing of cancer cells [39]. Similarly, the combination of cabozantinib, a multi-kinase inhibitor, with nivolumab or ipilimumab, both immune checkpoint inhibitors, is being evaluated in clinical trials, with early results indicating potential benefits in terms of response rates and survival [40].

Challenges in combination therapy for HCC include the management of increased toxicity, potential drug-drug interactions, and the complexity of identifying the most effective and safe combinations. The heterogeneity of HCC and the underlying liver disease in many patients further complicate treatment, necessitating careful patient selection and monitoring. Biomarker-driven approaches are being explored to identify patients who are most likely to benefit from specific combinations, aiming to tailor therapies to individual patient profiles [41].

Future directions for research in combination therapies for HCC include optimizing the sequencing and timing of different agents, exploring novel combinations, and integrating emerging therapies such as oncolytic viruses and CAR-T cells. Ongoing clinical trials are expected to provide further insights into the efficacy and safety of various combination regimens, potentially leading to new standards of care and improved outcomes for patients with HCC [42].

VII. Conclusion

The treatment landscape of hepatocellular carcinoma (HCC) has evolved significantly, with advancements in targeted therapies, immunotherapies, and combination regimens offering new hope for patients. Conventional treatments such as surgical resection, liver transplantation, and locoregional therapies remain essential for early-stage HCC, yet the integration of targeted therapies like sorafenib and lenvatinib has improved outcomes for advanced disease. The introduction of immune checkpoint inhibitors, including nivolumab and pembrolizumab, has further revolutionized HCC management, particularly when used in combination with other treatments, as exemplified by the atezolizumab-bevacizumab regimen. Despite the progress, challenges such as treatment resistance and increased toxicity necessitate ongoing research to optimize these therapeutic strategies. Future directions focus on refining combination therapies, developing biomarker-driven approaches, and exploring novel modalities to enhance efficacy and safety, ultimately aiming to improve survival and quality of life for HCC patients.

VIII. References

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-73.e1.
3. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(12):1342-59.e2.
4. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-14.
5. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450-62.
6. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for

*Corresponding Author: **Kirolos Eskandar**

© Copyright 2024 GSAR Publishers All Rights Reserved

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599-616.
7. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-73.
8. Finn RS, Zhu AX. Evolution of systemic therapy for hepatocellular carcinoma. Hepatology. 2020;73(S1):150-7.
9. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492-502.
10. Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020;38(26):2960-70.
11. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53.
12. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-73.e1.
13. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(12):1342-59.e2.
14. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450-62.
15. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1).
16. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10(11):656-65.
17. Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016;65(5):1031-42.
18. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology. 2015;149(5):1226-39.e4.
19. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12(7):408-24.
20. Nishida N, Goel A. Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics. 2011;12(2):130-7.
21. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-14.
22. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-9.
23. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429-42.
24. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology. 2010;78 Suppl 1:113-24.
25. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599-616.
26. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
27. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.
28. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-73.
29. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714-26.
30. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, et al. Antitumor activity of lenvatinib (E7080) in hepatocellular carcinoma models: actions through multiple receptor tyrosine kinases. Cancer Chemother Pharmacol. 2014;74(4):787-95.
31. Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020;38(26):2960-70.
32. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492-502.

*Corresponding Author: **Kirolos Eskandar**
© Copyright 2024 GSAR Publishers All Rights Reserved

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

33. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940-52.
34. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-905.
35. Duffy AG, Greten TF. Immunological off-target effects of standard treatments in hepatocellular carcinoma: implications for immunotherapy. Hepatology. 2017;66(2):698-706.
36. Haanen JBAG, Thienen JV, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol. 2015;42(3):423-8.
37. Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377(25):2500-1.
38. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-905.
39. Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020;38(26):2960-70.
40. Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Cohort 4 Study. JAMA Oncol. 2020;6(11).
41. Haanen JBAG, Thienen JV, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol. 2015;42(3):423-8.
42. Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer. 2016;122(3):367-77.

*Corresponding Author: **Kirolos Eskandar**

© Copyright 2024 GSAR Publishers All Rights Reserved

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.